October 1st, 2010
Podcast 103: eGFR and cardiovascular risk assessment
Welcome back. We take a look this week at a study from Iceland that looks at whether estimated glomerular filtration rates have a role in estimating cardiovascular risk. Our interview is with Cambridge University’s Dr. Emanuele Di Angelantonio. Your comments are welcome, both here and to my email address: jelia@jwatch.org. Interview-related links: BMJ study (free) BMJ meta-analysis (free) […]
July 1st, 2010
Podcast 94: What does a new meta-analysis tell us about statins and primary prevention?
A meta-analysis of 11 studies encompassing more than 60,000 subjects finds that statins don’t lower all-cause mortality in people without cardiovascular disease. One editorialist calls the study, just published in the Archives of Internal Medicine, “the cleanest and most complete meta-analysis of pharmacological lipid lowering for primary prevention.” One of the study’s principal authors, Kausik K. […]
February 19th, 2010
Podcast 75: Which regimen for hypertension?
Patients with hypertension at risk for cardiovascular events have done better with an ACE inhibitor-calcium channel blocker combination than with the ACE inhibitor plus hydrochlorothiazide. The ACCOMPLISH investigators have now reported on their analysis of progression-of-nephropathy outcomes in their trial. We interview the first author of the analysis, Dr. George Bakris of the University of […]
October 25th, 2009
Podcast 62: A conversation with Jane Kim about cost-effectiveness of vaccinating women with HPV vaccine after age 30.
The FDA seems set to announce a decision about vaccinating women past age 25 for HPV. A paper in the Annals of Internal Medicine this week indicates that such a strategy wouldn’t be cost-effective. Don’t be put off by “cost-effectiveness” or by the fact that we actually discuss “QALY”s. It’s all good. We’ve got Harvard […]
About the Podcast
Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.
Follow us:
